Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 25 results.
User Information
Export Records
  1. 1.   Crystal structure of a novel Kunitz type inhibitor, alocasin with anti-Aedes aegypti activity targeting midgut proteases
  2. Vajravijayan, Senthilvadivel; Pletnev,Sergei; Pletnev, Vladimir Z.; Nandhagopal, Narayanasamy; Gunasekaran, Krishnasamy
  3. PEST MANAGEMENT SCIENCE. 2018, DEC; 74(12): 2761-2772.
  1. 2.   Genotypic Resistance at Viral Rebound Among Patients Who Received Lopinavir/Ritonavir-Based or Efavirenz-Based First Antiretroviral Therapy in South Africa
  2. Dlamini, J. N.; Hu, Z. H.; Ledwaba, J.; Morris, L.; Maldarelli, F. M.; Dewar, R. L.; Highbarger, H. C.; Somaroo, H.; Sangweni, P.; Follmann, D. A.; Pau, A. K.; Phidisa, I. I. S. T.
  3. Jaids-Journal of Acquired Immune Deficiency Syndromes. 2011, Nov; 58(3): 304-308.
  1. 3.   Identification of a Potential Pharmacological Sanctuary for HIV Type 1 in a Fraction of CD4(+) Primary Cells
  2. Valentin, A.; Morrow, M.; Poirier, R. H.; Aleman, K.; Little, R.; Yarchoan, R.; Pavlakis, G. N.
  3. Aids Research and Human Retroviruses. 2010, Jan; 26(1): 79-88.
  1. 4.   Prednisolone pharmacokinetics in the presence and absence of Ritonavir after oral prednisone administration to healthy volunteers
  2. Penzak, S. R.; Fomnentini, E.; Alfaro, R. M.; Long, M.; Natarajan, V.; Kovacs, J.
  3. Jaids-Journal of Acquired Immune Deficiency Syndromes. 2005, DEC 15; 40(5): 573-580.
  1. 5.   Resistance of human immunodeficiency virus type 1 to the high-mannose binding agents cyanovirin N and concanavalin A
  2. Witvrouw, M.; Fikkert, V.; Hantson, A.; Pannecouque, C.; O'Keefe, B. R.; McMahon, J.; Stamatatos, L.; De Clercq, E.; Bolmstedt, A.
  3. Journal of Virology. 2005, JUN; 79(12): 7777-7784.
  1. 6.   A novel and efficient approach to discriminate between pre- and post-transcription HIV inhibitors
  2. Daelemans, D.; Pannecouque, C.; Pavlakis, G. N.; Tabarrini, O.; De Clercq, E.
  3. Molecular Pharmacology. 2005, MAY; 67(5): 1574-1580.
  1. 7.   Ritonavir decreases the nonrenal clearance of digoxin in healthy volunteers with known MDR1 genotypes
  2. Penzak, S. R.; Shen, J. M.; Alfaro, R. M.; Remaley, A. T.; Natarajan, V.; Falloon, J.
  3. Therapeutic Drug Monitoring. 2004 26(3): 322-330.
  1. 8.   Action of Anti-HIV drugs and resistance: Reverse transcriptase inhibitors and protease inhibitors
  2. Imamichi, T.
  3. Current Pharmaceutical Design. 2004 10(32): 4039-4053.
  1. 9.   Suppression of cerebrospinal fluid HIV burden in antiretroviral naive patients on a potent four-drug antiretroviral regimen
  2. Polis, M. A.; Suzman, D. L.; Yoder, C. P.; Shen, J. A.; Mican, J. M.; Dewar, R. L.; Metcalf, J. A.; Falloon, J.; Davey, R. T.; Kovacs, J. A.; Feinberg, M. B.; Masur, H.; Piscitelli, S. C.
  3. Aids. 2003 17(8): 1167-1172.
  1. 10.   Antiviral and immunological benefits in HIV patients receiving intranasal peptide T (DAPTA)
  2. Polianova, M. T.; Ruscetti, F. W.; Pert, C. B.; Tractenberg, R. E.; Leoung, G.; Strang, S.; Ruff, M. R.
  3. Peptides. 2003 24(7): 1093-1098.
  1. 11.   Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: Effects on virologic, immunologic, and toxicity parameters
  2. Dybul, M.; Chun, T. W.; Yoder, C.; Hidalgo, B.; Belson, M.; Hertogs, K.; Larder, B.; Dewar, R. L.; Fox, C. H.; Hallahan, C. W.; Justement, J. S.; Migueles, S. A.; Metcalf, J. A.; Davey, R. T.; Daucher, M.; Pandya, P.; Baseler, M.; Ward, D. J.; Fauci, A. S.
  3. Proceedings of the National Academy of Sciences of the United States of America. 2001 98(26): 15161-15166.
  1. 12.   Effect of chemokine receptor gene polymorphisms on the response to potent antiretroviral therapy
  2. O'Brien, T. R.; McDermott, D. H.; Ioannidis, J. P. A.; Carrington, M.; Murphy, P. M.; Havlir, D. V.; Richman, D. D.
  3. Aids. 2000 14(7): 821-826.
  1. 13.   The aspartic proteinase from Saccharomyces cerevisiae folds its own inhibitor into a helix
  2. Li, M.; Phylip, L. H.; Lees, W. E.; Winther, J. R.; Dunn, B. M.; Wlodaawer, A.; Kay, J.; Gustchina, A.
  3. Nature Structural Biology. 2000 7(2): 113-117.
  1. 14.   Cloning of the bovine leukemia virus proteinase in Escherichia coli and comparison of its specificity to that of human T-cell leukemia virus proteinase
  2. Zahuczky, G.; Boross, P.; Bagossi, P.; Emri, G.; Copeland, T. D.; Oroszlan, S.; Louis, J. M.; Tozser, J.
  3. Biochimica et Biophysica Acta - Protein Structure & Molecular Enzymology. 2000 1478(1): 1-8.
  1. 15.   Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain
  2. Sei, S.; Yang, Q. E.; O'Neill, D.; Yoshimura, K.; Nagashima, K.; Mitsuya, H.
  3. Journal of Virology. 2000 74(10): 4621-4633.
  1. 16.   Papuamides A-D, HIV-inhibitory and cytotoxic depsipeptides from the sponges Theonella mirabilis and Theonella swinhoei collected in Papua New Guinea
  2. Ford, P. W.; Gustafson, K. R.; McKee, T. C.; Shigematsu, N.; Maurizi, L. K.; Pannell, L. K.; Williams, D. E.; de Silva, E. D.; Lassota, P.; Allen, T. M.; van Soest, R.; Andersen, R. J.; Boyd, M. R.
  3. Journal of the American Chemical Society. 1999 121(25): 5899-5909.
  1. 17.   Nonpeptidic HIV protease inhibitors possessing excellent antiviral activities and therapeutic indices. PD 178390: A lead HIV protease inhibitor
  2. Prasad, J.; Boyer, F. E.; Domagala, J. M.; Ellsworth, E. L.; Gajda, C.; Hamilton, H. W.; Hagen, S. E.; Markoski, L. J.; Steinbaugh, B. A.; Tait, B. D.; Humblet, C.; Lunney, E. A.; Pavlovsky, A.; Rubin, J. R.; Ferguson, D.; Graham, N.; Holler, T.; Hupe, D.; Nouhan, C.; Tummino, P. J.; Urumov, A.; Zeikus, E.; Zeikus, G.; Gracheck, S. J.; Saunders, J. M.
  3. Bioorganic & Medicinal Chemistry. 1999 7(12): 2775-2800.
  1. 18.   Structure-based design of HIV protease inhibitors: pharmacokinetic optimization
  2. Stinson, S. F.; Randad, R. S.; Clanton, D.; House, T.; Lubkowska, L.; Erickson, J. W.
  3. HIV Pathogenesis and Treatment Conference. 1998, 56 (abstract no. 2039).
  1. 19.   Importance of molecular flexibility for the resistance of HIV-1 protease inhibitors
  2. Kato, R.; Yusa, K.; Gulnik, S. V.; Bhat, T.; Hayashi, H.; Mitsuya, H.; Erickson, J. W.
  3. International Conference on AIDS. 1998, 12 67-68.
  1. 20.   Thermodynamics and proton uptake for pepstatin binding to retroviral and eukaryotic aspartic proteases
  2. Xie, D.; Gulnik, S.; Collins, L.; Gustchina, E.; Bhat, T. N.; Erickson, J. W.
  3. Advances in Experimental Medicine and Biology. 1998 436: 381-386.
  1. 21.   Application of restriction enzyme analysis to screen drug-resistant mutations in HIV-protease and in proteolytic cleavage sites in the gag region
  2. Vasudevachari, M. B.; Imamichi, T.; Imamichi, H.; Zhang, Y. M.; Salzman, N. P.
  3. Conference on Retroviruses and Opportunistic Infections. 1997, 176 (abstract no. 606).
  1. 22.   Emergence of drug resistant HIV variants with mutations in the protease gene and gag cleavage sites during indinavir therapy
  2. Zhang, Y. M.; Imamichi, H.; Falloon, J.; Lane, H. C.; Vasudevachari, M. B.; Imamichi, T.; Salzman, N. P.
  3. Conference on Retroviruses and Opportunistic Infections. 1997, 175 (abstract no. 602).
  1. 23.   Escape Mutants of Hiv-1 Proteinase - Enzymic Efficiency and Susceptibility to Inhibition
  2. Wilson, S. I.; Phylip, L. H.; Mills, J. S.; Gulnik, S. V.; Erickson, J. W.; Dunn, B. M.; Kay, J.
  3. Biochimica et Biophysica Acta - Protein Structure & Molecular Enzymology. 1997 1339(1): 113-125.
  1. 24.   Identification of Human Neutrophil-Derived Cathepsin G and Azurocidin/Cap37 As Chemoattractants For Mononuclear Cells and Neutrophils
  2. Chertov, O.; Ueda, H.; Xu, L. L.; Tani, K.; Murphy, W. J.; Wang, J. M.; Howard, O. M. Z.; Sayers, T. J.; Oppenheim, J. J.
  3. Journal of Experimental Medicine. 1997 186(5): 739-747.
  1. 25.   HIV pharmacogenetics and pharmacogenomics: From bench to bedside
  2. Limou, Sophie; Winkler,Cheryl; Wester, C. William
  3. 2019; 185-222.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel